Surfing The NASH Tsunami Podcast

Driving The Discussion In Fatty Liver Disease

learn more about NASH Fatty Liver FDA NAFLD education EchoSens Diagnostic Tests FIB 4 COVID 19 Semaglutide Drug Trial Obesity TLMDx 2020 Siemens Genfit EASL cirrhosis obeticholic acid Diabetes TrialDesign Patient Advocacy social policy NASH TAG Phase3 Global Liver Institute MRI-PDFF Testing non invasive liver testing FibroScan AASLD

Drug developers, investors, researchers, and corporate executives…

Every week, a global community of Fatty Liver Disease stakeholders comes together to explore the most important challenges in diagnosing, treating, and developing medications for patients with Fatty Liver Diseases.

Join hepatology researcher and Key Opinion Leader Dr. Stephen Harrison, liver wellness advocate Louise Campbell MSc AP., Forecasting and Pricing guru Roger Green, M.B.A., and their weekly guests as they discuss these issues from their own unique perspectives on the Surfing the NASH Tsunami podcast.

This is truly an excellent podcast. Roger Green is joined by Akero Therapeutics' Kitty Yale, Manal Abdelmalek (Duke Uni), Naim Alkhouri (Arizona Liver Health) and Stephen Harrison from Pinnacle Clinical Research. They go through the FDA's recent webcast and dissect the meaning and directions laid out. Interesting points around histology remaining the surrogate for the evaluation of NASH and how we need to have a better way of quantifying NASH histology

A podcast for the NASH community! So many relevant topics. There are guest speakers almost every week who contribute a new energy to each episode. Keep up the good work coming!

The host and other speakers are engaging to listen to yet not too serious or noting. I find mysweldf learning without trying. Excellent to have this on while working at home or driving while running errands.

We have sorely needed a podcast that allows clinicians and academics to focus own major issues in NASH and NAFLD. Their recent coverage of ILC was timely and incisive. I find myself discussing the episodes with colleagues and Twitter buddies.

Most Recent Podcast

S2-E9 – Novel Approaches to Drug-Free Treatment of Early Fatty Liver Disease

March 4, 2021

Donna Cryer joins the Surfers to discuss the importance of identity in lifestyle modification, after which our sponsors from Echosens present LIVErHEALTHY, a program that combines non-invasive testing, technology-enabled behavior support and a food and nutrition element.

Recent Episodes & Conversations

S2-E8.3 – Previewing NASH-TAG 2021: Two intriguing side conversations

February 27, 2021

This conversation integrates two significant side conversations during the review of the NASH-TAG 2021 agenda, one about creativity and intellectual ferment and the other about what we can learn from COVID-19 about how to motivate patients.

S2-E8.2 – Previewing NASH-TAG 2021: Day Two

February 27, 2021

Stephen Harrison previews Day Two of NASH-TAG while Ian Rowe, Louise Campbell and Roger Green the issues that each of them anticipate most eagerly

S2-E8.1 – Previewing NASH-TAG 2021: Day One

February 27, 2021

Stephen Harrison discusses the history of NASH-TAG and what makes it special while previewing Day One of the 2021 meeting

S2-E8 – Previewing NASH-TAG 2021

February 24, 2021

Stephen Harrison previews NASH-TAG 2021, the pre-eminent NASH drug development meeting, which will take place from March 10-12

S2-E7.3 – The newer diabetes drugs and NASH: Educating and Motivating Stakeholders

February 20, 2021

The panelists consider the barriers to bringing NASH into central consciousness in diabetes therapy and some keys to success.

S2-E7.2 – The Newer Diabetes Drugs and NASH: How T2D Patients are likely to respond

February 20, 2021

Wayne Eskridge describes some of the opportunities and concerns that affect diabetic patients might experience as they learn about NASH and the liver issues related to diabetes.

S2-E7.1 – The Newer Diabetes Drugs and NASH: Modes of Action

February 20, 2021

Jörn Schattenberg reviews modes of action for GLP-1 agonists and SGLT-2 inhibitors and discusses the data that exist in NAFLD and NASH

S2-E7 – The Newer Diabetes Drugs and Patients with NASH

February 17, 2021

Jörn Schattenberg and Fatty Liver Foundation President Wayne Eskridge join Louise and Roger to consider the current and future roles that GLP-1 receptor agonists like semaglutide and SGLT-2 inhibitors like Jardiance in treating NASH patients.

Join The Discussion

Dive deep with the surfers! We launched our new private discussion groups on LinkedIn and Facebook so that our listeners get direct access to our surfers about current topics.